Condition: Advanced Metastatic Castration Resistant Prostate Cancer · Sponsor: Shenzhen Ionova Life Sciences Co., Ltd.
This is a Phase 1 and Phase 2 study to evaluate the safety and antitumor activity of INV-9956 in adult patients with advanced metastatic Castration Resistant Prostate Cancer.
This description comes directly from the study's public registry record.
Yi Zhu, MD, MBA · 1 908 240 7514 · yi.zhu@ionovabio.com
Always discuss trial participation with your own doctor first.
| Honor Health | Scottsdale, Arizona, United States | Recruiting |
| Hoag Family Cancer Institute | Newport Beach, California, United States | Recruiting |
| UC Irvine Medical Center | Orange, California, United States | Recruiting |
| Next Oncology - Houston | Houston, Texas, United States | Recruiting |
| UT Health | San Antonio, Texas, United States | Recruiting |
| NEXT Oncology | Fairfax, Virginia, United States | Recruiting |
| Summit Cancer Centers | Spokane, Washington, United States | Recruiting |
| Beijing GoBroad Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| The First Affiliated Hospital of Fujian Medical University | Fuzhou, Fujian, China | Recruiting |
| The First People's Hospital of Foshan | Foshan, Guangdong, China | Not Yet Recruiting |
| He'nan Cancer Hospital | Zhengzhou, He'Nan, China | Recruiting |
| Hu'nan Cancer Hospital | Changsha, Hu'Nan, China | Not Yet Recruiting |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06609005